- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04477928
General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery (PLEDGE)
Sanford Population Level Estimation of Type 1 Diabetes Risk GEnes in Children
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Most children with type 1 diabetes (T1D) do not have a family member with diabetes and often are not diagnosed until the child is very sick. Research suggests that screening and identifying children at risk for T1D autoantibodies can prevent serious illness at the time of diagnosis and improve long-term health outcomes.
The investigators will screen children, ages 0-5.99 or 9-16 years for blood markers related to T1D and celiac disease during routine healthcare delivery at birth, 1, 2 and 5 years, or once between 9 and 16 years of age. Children with confirmed autoantibodies will be offered participation in other monitoring or prevention trials (T1D), or referred to clinical care (celiac).
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Ann Mays, RN, CPN
- Phone Number: 605-312-6052
- Email: ann.mays@sanfordhealth.org
Study Locations
-
-
Minnesota
-
Bemidji, Minnesota, United States, 56601
- Recruiting
- Sanford Bemidji Region Clinics
-
Contact:
- Ann Mays, RN, CPN
- Phone Number: 605-312-6052
- Email: ann.mays@sanfordhealth.org
-
Principal Investigator:
- Kurt Griffin, PhD, MD
-
-
North Dakota
-
Bismarck, North Dakota, United States, 58501
- Recruiting
- Sanford Bismarck Region Clinics
-
Contact:
- Ann Mays, RN, CPN
- Phone Number: 605-312-6052
- Email: ann.mays@sanfordhealth.org
-
Principal Investigator:
- Kurt Griffin, PhD, MD
-
Fargo, North Dakota, United States, 58112
- Recruiting
- Sanford Fargo Region Clinics
-
Principal Investigator:
- Kurt Griffin, PhD, MD
-
Contact:
- Ann Mays
- Phone Number: 605-312-6052
- Email: ann.mays@sanfordhealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57105
- Recruiting
- Sanford Sioux Falls Region Clinics
-
Principal Investigator:
- Kurt Griffin, PhD, MD
-
Contact:
- Ann Mays
- Phone Number: 605-312-6052
- Email: ann.mays@sanfordhealth.org
-
Sub-Investigator:
- Sharon Hunt, BS, MS, MBA
-
Sub-Investigator:
- Candice Nelson, MD, FAAP
-
Sub-Investigator:
- Stephanie Hanson, MD, FAAP
-
Sub-Investigator:
- Louis Casas, MD, FAAP
-
Sub-Investigator:
- Brenda Thurlow, MD, FAAP
-
Sub-Investigator:
- Kyle Baum, MD
-
Sub-Investigator:
- Ann Mays, RN, CPN
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Children born at and/or followed at Sanford Health System facilities:
- . 0-5 years of age;
- . 9-16 years of age;
- . Siblings of children known to have T1D-relevant antibodies, ages 6 to 17 years old.
Description
Inclusion Criteria:
- Newborn Entry: Viable, term infants, defined as 36 weeks gestation by either dates or ultrasound who are born to pregnant women, 18 years or older, who are willing and able to provide informed consent (IC) prior to the onset of active labor. Who are born at a Sanford Health Hospital and plan to have routine well-child care at a Sanford Clinic
- Pediatric Entry: Children less than 6 years of age who receive their routine care at a Sanford facility and whose parents are able to provide IC.
- Adolescent Entry: Children, ages 9-16 years old, who receive their routine care at a Sanford facility and whose parents are able to provide IC.
- Siblings of children known to have T1D-relevant antibodies; ages 6 to 17 years old who receive care at a Sanford clinic
- Have an active MyChart account (with proxy access).
Exclusion Criteria:
- Subject is in the opinion of the investigator, unable to comply with the requirements of the study protocol.
- Children known to have T1D
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Study Group
Children receiving routine care at a Sanford facility
|
Opt-in: Differential Gene Expression from cord blood at birth and peripheral blood at 12 months of age
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Demonstrated feasibility of large-scale population screening, as evidenced by:
Time Frame: By year 10 of the study
|
|
By year 10 of the study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Seroconversion rates for T1D-relevant and celiac autoantibodies
Time Frame: By year 10 of study
|
By year 10 of study
|
Percentage of T1D seropositive subjects who enroll in another T1D monitoring or prevention study.
Time Frame: By year 10 of study
|
By year 10 of study
|
Percentage of celiac seropositive subjects referred on to GI or primary care
Time Frame: By year 10 of study
|
By year 10 of study
|
The percentage of celiac seropositive subjects who were evaluated in clinical setting
Time Frame: By year 10 of study
|
By year 10 of study
|
The rate of development of overt hyperglycemia consistent with T1D (Stage 3).
Time Frame: By year 10 of study
|
By year 10 of study
|
Proportion of participants developing overt hyperglycemia consistent with T1D (Stage 3), who present in diabetic ketoacidosis (DKA)
Time Frame: By year 10 of study
|
By year 10 of study
|
Number and type of procedure-related adverse events
Time Frame: By year 10 of study
|
By year 10 of study
|
Assessment of costs associated with implementation of study compared to potential impacts on cost and quality of life.
Time Frame: By year 10 of study
|
By year 10 of study
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kurt Griffin, PhD, MD, Sanford Research
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PLEDGE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on Sera and whole blood sampling
-
Centre Hospitalier Universitaire de NīmesTerminated
-
TakedaCompletedToxicityUnited States, Argentina, Poland, South Africa, Russian Federation, Netherlands, Chile, Canada, Germany, Latvia, Finland, United Kingdom, Czech Republic, Slovakia
-
Medical University of GrazJoanneum Research Forschungsgesellschaft mbHCompleted
-
CardioRenalCompletedPotassium MeasurementBelgium
-
University Children's Hospital, ZurichUniversity Hospital, Geneva; University Children's Hospital BaselRecruitingImmunologic Deficiency SyndromesSwitzerland
-
Centre Hospitalier Universitaire DijonCompletedPatients With Intellectual Disabilities Without an Obvious Clinical Diagnosis | Patients With Normal Array CGH and Previous Negative Genetic Investigations (WES-solo or WES-trio)France
-
Assistance Publique - Hôpitaux de ParisUnknownSepsis | Acute Circulatory FailureFrance
-
Institut PasteurInstitut National de la Santé Et de la Recherche Médicale, France; University... and other collaboratorsUnknownEncephalitisVietnam, Cambodia, Lao People's Democratic Republic, Myanmar
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Rennes University HospitalCompletedMultiple SclerosisFrance